Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Large Granular Lymphocytic | 3 | 2013 | 22 | 1.450 |
Why?
|
Carcinoma, Pancreatic Ductal | 6 | 2022 | 1506 | 1.430 |
Why?
|
Pancreatic Neoplasms | 8 | 2022 | 5000 | 1.020 |
Why?
|
Leucovorin | 2 | 2021 | 602 | 0.920 |
Why?
|
Fluorouracil | 2 | 2021 | 1623 | 0.730 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 113 | 0.660 |
Why?
|
Liver Neoplasms | 3 | 2021 | 4091 | 0.610 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2020 | 336 | 0.610 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 261 | 0.610 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 183 | 0.530 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 607 | 0.520 |
Why?
|
Fever | 1 | 2020 | 1589 | 0.460 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1140 | 0.460 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2012 | 66 | 0.440 |
Why?
|
Immunotherapy | 3 | 2022 | 4118 | 0.440 |
Why?
|
Superior Vena Cava Syndrome | 1 | 2012 | 49 | 0.440 |
Why?
|
Peptides | 2 | 2021 | 4434 | 0.430 |
Why?
|
Adrenal Gland Diseases | 1 | 2012 | 133 | 0.430 |
Why?
|
Cellulitis | 1 | 2014 | 233 | 0.430 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13732 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11317 | 0.400 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 652 | 0.390 |
Why?
|
Vascular Neoplasms | 1 | 2012 | 183 | 0.380 |
Why?
|
Deoxycytidine | 1 | 2014 | 834 | 0.380 |
Why?
|
Hematologic Diseases | 1 | 2013 | 494 | 0.370 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 2085 | 0.360 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 713 | 0.350 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2014 | 1001 | 0.340 |
Why?
|
Catheter Ablation | 1 | 2021 | 2558 | 0.340 |
Why?
|
Adenocarcinoma | 3 | 2016 | 6371 | 0.330 |
Why?
|
Autoimmune Diseases | 3 | 2015 | 2109 | 0.330 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1255 | 0.310 |
Why?
|
Lung Neoplasms | 3 | 2020 | 12567 | 0.300 |
Why?
|
Esophageal Neoplasms | 1 | 2016 | 1534 | 0.300 |
Why?
|
Autoimmunity | 1 | 2014 | 1332 | 0.290 |
Why?
|
Hemorrhage | 2 | 2013 | 3273 | 0.250 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1437 | 0.240 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1699 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5482 | 0.210 |
Why?
|
Amphetamine-Related Disorders | 1 | 2020 | 64 | 0.200 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 1566 | 0.200 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 2529 | 0.190 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3130 | 0.190 |
Why?
|
Niacinamide | 1 | 2021 | 434 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3694 | 0.170 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2018 | 58 | 0.170 |
Why?
|
Organoids | 2 | 2022 | 651 | 0.170 |
Why?
|
Pregnancy Complications | 1 | 2012 | 2827 | 0.170 |
Why?
|
Liposomes | 1 | 2021 | 751 | 0.170 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 550 | 0.160 |
Why?
|
Valproic Acid | 1 | 2020 | 447 | 0.160 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 4042 | 0.150 |
Why?
|
Humans | 33 | 2022 | 715124 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 622 | 0.140 |
Why?
|
Receptors, CXCR4 | 1 | 2020 | 735 | 0.140 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 2014 | 30 | 0.130 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2014 | 54 | 0.130 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1055 | 0.130 |
Why?
|
Pyoderma Gangrenosum | 1 | 2014 | 72 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5238 | 0.120 |
Why?
|
Pancytopenia | 1 | 2014 | 106 | 0.120 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3071 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 878 | 0.120 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2014 | 292 | 0.120 |
Why?
|
Bile Ducts | 1 | 2014 | 290 | 0.120 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 2075 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2020 | 838 | 0.120 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 316 | 0.120 |
Why?
|
Aged, 80 and over | 7 | 2021 | 58505 | 0.110 |
Why?
|
Lymphatic Metastasis | 1 | 2020 | 2971 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2014 | 5098 | 0.110 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 345 | 0.110 |
Why?
|
Vena Cava, Superior | 1 | 2012 | 181 | 0.100 |
Why?
|
Treatment Outcome | 4 | 2021 | 62186 | 0.100 |
Why?
|
Immunosuppressive Agents | 2 | 2013 | 4208 | 0.090 |
Why?
|
Vasculitis | 1 | 2013 | 518 | 0.090 |
Why?
|
Blood Platelets | 1 | 2020 | 2474 | 0.090 |
Why?
|
Hepatitis B | 1 | 2014 | 643 | 0.090 |
Why?
|
Nanoparticles | 1 | 2021 | 1939 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2154 | 0.090 |
Why?
|
Thalidomide | 1 | 2014 | 919 | 0.090 |
Why?
|
Prevalence | 3 | 2015 | 14869 | 0.090 |
Why?
|
Interferon-alpha | 1 | 2013 | 897 | 0.090 |
Why?
|
Lymph Nodes | 1 | 2020 | 3433 | 0.090 |
Why?
|
Rheumatic Diseases | 1 | 2014 | 538 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2020 | 8674 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1573 | 0.080 |
Why?
|
Boronic Acids | 1 | 2012 | 996 | 0.080 |
Why?
|
Male | 13 | 2021 | 351081 | 0.080 |
Why?
|
Aged | 7 | 2021 | 162674 | 0.080 |
Why?
|
Sodium | 1 | 2012 | 1608 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4250 | 0.080 |
Why?
|
Methotrexate | 1 | 2013 | 1723 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3050 | 0.070 |
Why?
|
Pyrazines | 1 | 2012 | 1269 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2013 | 1932 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1004 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1902 | 0.070 |
Why?
|
Multiple Myeloma | 2 | 2014 | 5142 | 0.070 |
Why?
|
Survival Rate | 1 | 2020 | 13255 | 0.070 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 3595 | 0.070 |
Why?
|
Prospective Studies | 5 | 2022 | 51181 | 0.070 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18345 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1642 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2014 | 2128 | 0.060 |
Why?
|
Animals | 6 | 2020 | 170726 | 0.060 |
Why?
|
Lung Diseases | 1 | 2013 | 1897 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 8093 | 0.060 |
Why?
|
Recurrence | 1 | 2014 | 8269 | 0.060 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6566 | 0.050 |
Why?
|
Neoplasms | 2 | 2020 | 20515 | 0.050 |
Why?
|
Middle Aged | 6 | 2021 | 214871 | 0.050 |
Why?
|
Heart Transplantation | 1 | 2013 | 3081 | 0.050 |
Why?
|
Female | 7 | 2021 | 377334 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 3677 | 0.050 |
Why?
|
Adult | 3 | 2021 | 212129 | 0.050 |
Why?
|
Mice | 4 | 2020 | 80995 | 0.050 |
Why?
|
Biopsy | 1 | 2012 | 6750 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 328 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8016 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2013 | 2964 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7225 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 361 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7045 | 0.040 |
Why?
|
Signal Transduction | 2 | 2018 | 23973 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2021 | 72255 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2012 | 11192 | 0.040 |
Why?
|
Prognosis | 2 | 2020 | 29168 | 0.040 |
Why?
|
Endopeptidases | 1 | 2020 | 843 | 0.040 |
Why?
|
Immunomodulation | 1 | 2020 | 536 | 0.040 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1923 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2842 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2020 | 10800 | 0.030 |
Why?
|
Polysaccharides | 1 | 2020 | 993 | 0.030 |
Why?
|
Apoptosis | 2 | 2020 | 10112 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3825 | 0.030 |
Why?
|
Taiwan | 1 | 2014 | 490 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2014 | 364 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2014 | 420 | 0.030 |
Why?
|
Mutation | 1 | 2018 | 29442 | 0.030 |
Why?
|
Knee | 1 | 2014 | 246 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16943 | 0.030 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1034 | 0.030 |
Why?
|
Pregnancy | 1 | 2012 | 27180 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 10660 | 0.020 |
Why?
|
Tacrolimus | 1 | 2013 | 714 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 6131 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1892 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 10123 | 0.020 |
Why?
|
China | 1 | 2014 | 2272 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2016 | 1093 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2014 | 1785 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 11285 | 0.020 |
Why?
|
Myocarditis | 1 | 2012 | 680 | 0.020 |
Why?
|
Amyloidosis | 1 | 2012 | 797 | 0.020 |
Why?
|
Anticoagulants | 1 | 2020 | 4368 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2013 | 1366 | 0.010 |
Why?
|
Risk | 1 | 2014 | 9772 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9968 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13594 | 0.010 |
Why?
|
Skin | 1 | 2014 | 4354 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10423 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 21790 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 70704 | 0.010 |
Why?
|
Concepts
(164)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_